Clinical trials: Severe Pneumonia
Covid19, Acute Respiratory Distress Syndrome
Clinical Features of COVID-19 Patients
The data were retrospectively collected during the first and the second wave of epidemic in COVID-19 patients with Severe Acute Respiratory Syndrome Coronavirus 2, at the moment of intensive care unit admission and during the in…
- Conditions
- Covid19, Acute Respiratory Distress Syndrome, Ventilatory Failure
- Trial name
- NCT04815304
- Testing
- peripheral lymphocytes subsets
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- San Salvatore Hospital of L'Aquila
Post-intensive Care Syndrome, COVID-19
Clinical and Functional Characteristics of Patients Admitted for Severe COVID-19 Pneumonia
This research protocol aims to evaluate the impact of severe COVID-19 pneumonia requiring invasive mechanical ventilation (IMV) on health-related quality of life (HRQoL), functional capacity, muscle strength, and nutritional…
- Trial name
- EQOL-COVID (NCT06727474)
- Testing
- Health-Related Quality of Life (HRQoL) with EQ-5D-3L
- Where
- Argentina
- Volunteers
- 51 people
- Sponsor
- Hospital Nacional Profesor Alejandro Posadas
Ventilator Associated Pneumonia
Efficacy of Two Intermittent Subglottic Secretion
The purpose of this study is to determine the efficacy of intermittent subglottic secretion lavage combined with aspiration preventing ventilator associated pneumonia in patients with severe neurological disease
- Trial name
- NCT03871985
- Testing
- Subglottic secretion lavage combined with aspiration, Subglottic secretion aspiration
- Volunteers
- 234 people
- Sponsor
- The First Hospital of Jilin University
Mesenchymal Stem Cell, COVID-19 Pneumonia
UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients With Refractory Hypoxia
The goal of this randomized, controlled, open-labeled interventional clinical trial is to test the efficacy and safety of umbilical cord mesenchymal stem cells (UC- MSCs) in the treatment of severe and critical COVID-19 patients…
- Trial name
- NCT05689008
- Testing
- UC-MSCs treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai East Hospital
Ocular Graft-versus-host Disease
Allogeneic Platelet Lysate Eye Drops for the Treatment of Severe Chronic Ocular Graft-versus-host Disease
The study evaluates the efficacy and safety of allogeneic platelet lysate eye drops in patients with severe ocular graft versus host disease refractory to conventional systemic and local treatments.
- Trial name
- NCT05311514
- Testing
- Allogeneic platelet lysate eye drops
- Where
- Russia
- Volunteers
- 38 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Long COVID
Study of LAU-7b for the Treatment of Long COVID in Adults
ESSOR is a double-blind, placebo-controlled study of the orally-administered antiviral and inflammation-controlling LAU-7b for the treatment of adults with Long COVID and moderate to severe symptoms.
- Trial name
- ESSOR (NCT05999435)
- Testing
- LAU-7b for 3 cycles
- Where
- 5 sites in Canada
- Volunteers
- 272 people
- Sponsor
- Laurent Pharmaceuticals Inc.
Childhood Severe Illness, Pneumonia
Tools for the Integrated Management of Childhood Illness: Cross-country Quasi-experimental Pre-post Study in Kenya and Senegal
By introducing pulse oximetry, with or without clinical decision support algorithms, to primary care facilities in India, Kenya, Senegal and Tanzania, the Tools for Integrated Management of Childhood Illness (TIMCI) project aims…
- Conditions
- Childhood Severe Illness, Pneumonia, Primary Health Care, Hypoxia
- Trial name
- TIMCI (NCT05065320)
- Where
- 2 sites in Kenya, Senegal
- Volunteers
- 51,590 people, healthy volunteers welcome
- Sponsor
- Swiss Tropical & Public Health Institute
Pneumonia
A Randomized Controlled Trial (RCT) of Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia Caused by Drug-resistant Gram-negative Bacilli
Through a prospective randomized controlled trial, we systematically evaluate the effects of Yiqi Huoxue Jiedu Formula combined with bacteriophage therapy on the bacterial clearance rate, disease improvement rate and mortality…
- Trial name
- NCT07338123
- Testing
- YHDF Drug, Bacteriophage
- Volunteers
- 240 people
- Sponsor
- Chinese PLA General Hospital
ARDS (Moderate or Severe)
Transpulmonary Pressure-guided Mechanical Ventilation Strategy in Right Ventricular Protection in Patients With ARDS
To verify whether the transpulmonary pressure-guided mechanical ventilation strategy can reduce right ventricular involvement, especially the incidence of acute cor pulmonale (ACP), in patients with moderate to severe ARDS…
- Trial name
- NCT07490925
- Testing
- Transpulmonary pressure guided mechanical ventilation strategy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Beijing Chao Yang Hospital
COVID-19
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
The purpose of this study is to learn about the side effects (safety) of the study medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate COVID-19 infection in adults with severe renal impairment.
- Trial name
- NCT05487040
- Testing
- PF-07321332 (nirmatrelvir)/ritonavir
- Where
- 52 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Pseudomonas Infections, Pseudomonas Septicemia
Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis
The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype predominates in blood monocytes in…
- Conditions
- Pseudomonas Infections, Pseudomonas Septicemia, Pseudomonas; Pneumonia, Pseudomonal Bacteraemia
- Trial name
- MIPSA (NCT03044223)
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Ulm
COVID-19, Pneumonia
Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)
This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 168 eligible patients with severe novel coronavirus pneumonia.
- Trial name
- COVID-19 (NCT05702788)
- Testing
- Jaktinib hydrochloride tablets
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
COVID-19
Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19
Objective of the study: to investigate the effect of meglumine succinate solution on the dynamics of metabolic blood parameters and respiratory function of the lungs in intensive care patients with new coronavirus infection.
- Trial name
- CARECOVID (NCT05172180)
- Testing
- Reamberin, Ringer's solution
- Where
- Russia
- Volunteers
- 105 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Severe Pneumonia, Community-acquired Pneumonia
Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients
Ambroxol is a mucolytic containing an active N-desmethyl metabolite of bromhexine. It is approved by both the U.S. FDA and EMA to be marketed under several formulations including oral, nasal, oro-mucosal, rectal and intravenous…
- Conditions
- Severe Pneumonia, Community-acquired Pneumonia, Hospital-acquired Pneumonia, Critical Illness
- Trial name
- NCT05663905
- Testing
- Ambroxol Hydrochloride, Standard Therapy
- Where
- Malaysia
- Volunteers
- 32 people
- Sponsor
- National University of Malaysia
Covid 19
Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19
Acute Respiratory Distress Syndrome (ARDS) is the main cause of death from COVID-19. One of the main mechanisms for ARDS is the violent storm of cytokines and chemokines, which cause uncontrolled fatal systemic inflammation by…
- Trial name
- COVID-19 (NCT04416139)
- Testing
- Infusion IV of Mesenchymal Stem cells
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
SARS-CoV2
Clinical Features of Severe Patients With COVID-19
As coronavirus disease 2019 (COVID-19) spreads across the world, the intensive care unit (ICU) community must prepare for the challenges associated with this pandemic.
- Trial name
- NCT04450017
- Testing
- The demographic, clinical, laboratory, and instrumental data
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
Healthy Participants
Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants
The purpose of this study is to estimate the effect PF-07321332/Ritonavir and Ritonavir on Midazolam (a cytochrome P450 [CYP]3A4 substrate) in Healthy Adult Participants.
- Trial name
- NCT05032950
- Testing
- Midazolam, PF-07321332/ritonavir + Midazolam, Ritonavir + Midazolam
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Severe Acute Respiratory Syndrome, Coronavirus
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of CVnCoV at different dose levels.
- Conditions
- Severe Acute Respiratory Syndrome, Coronavirus, SARS-CoV-2, COVID-19
- Trial name
- NCT04449276
- Testing
- CVnCoV Vaccine
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- CureVac
Covid-19
Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia
The trial aims to assess the impact of cheap, licenced and widely available investigational products on the natural history of SARS-CoV-2 infection in 2 groups of patients - those with mild or moderate pneumonia (Cohort 1) and…
- Trial name
- PaTS-COVID (NCT04703608)
- Testing
- Ivermectin, ASP
- Where
- The Gambia
- Volunteers
- 1,200 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Cancer, COVID
Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection
Ivermectin plus losartan as prophilaxy to severe events in patients with cancer with recent diagnosis of COVID-19
- Conditions
- Cancer, COVID, Coronavirus Infection
- Trial name
- TITAN (NCT04447235)
- Testing
- Ivermectin, Losartan
- Where
- Brazil
- Volunteers
- 77 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.